In this video, Motley Fool health care analyst Max Macaluso takes a closer look at Amarin (AMRN 2.43%), which recently received approval from the Food and Drug Administration for its triglyceride-lowering drug Vascepa. The drug's excellent safety profile compared to other competitive drugs within the same space should definitely catch the eye of investors. However, because Vascepa hasn't received NCE status yet -- which would grant the company an extra two years of marketing exclusivity on top of the initial three -- enthusiasm may be somewhat tempered for the short term.
1 Reason to Buy Amarin Right Now, and 1 Reason to Sell
By Max Macaluso and austin smith – Nov 8, 2012 at 3:41PM
NASDAQ: AMRN
Amarin Plc
Market Cap
$400M
Today's Change
(-2.43%) $0.48
Current Price
$19.24
Price as of October 27, 2025 at 4:00 PM ET
Should you keep this drugmaker in your portfolio?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo